Stanford researchers in the Goldberg lab have developed a novel method for targeted gene therapy delivery to retinal astrocytes for the treatment of glaucoma and other optic neuropathies.
Stanford researchers in the Goldberg lab have discovered two novel gene therapy targets for the treatment of glaucoma and other optic neuropathies. Glaucoma is the leading cause of irreversible blindness world-wide, affecting millions of adults in the United States alone.
Researchers at Stanford University have developed a method to induce antigen-specific immunological tolerance to allow for more effective gene replacement therapy for Duchenne muscular dystrophy (DMD).
Researchers at Stanford have developed a new catalog of compact transcription effector domains and fused them onto DNA binding domains to engineer synthetic transcription factors.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an efficacious therapy for patients with life-threatening leukemias, but its use has been hindered by the limited availability of donors with matching HLA. Graft manipulation by removing ??
Researchers in Prof. Michael Lin's laboratory have developed a viral-based cancer therapy platform that could be used for targeting treatment to cancer cells with aberrant signaling in EGFR or HER2 pathways.
RNA replication and amplification have broad applications across biomedicine, but current methods are limited by a reliance on inefficient, multi-step protocols.
Researchers in Prof. Stephen Quake's laboratory have developed a CRISPER-Cas-based targeted endonuclease system designed to treat latent viral infections by attacking the viral genome.
Stanford researchers have developed a new class of materials that enable new strategies for the efficient delivery of messenger RNA (mRNA) into cells and animals. The delivery materials are easily prepared (2 steps), stable and readily tuned.